8-K: Ocuphire Pharma Announces Positive Subgroup Analysis from ZETA-1 Trial for Diabetic Retinopathy

Ocuphire Pharma's post-hoc analysis of the ZETA-1 trial shows a significant treatment benefit of APX3330 in a high-risk subgroup of patients with non-proliferative diabetic retinopathy (NPDR).

Summary

• Ocuphire Pharma has released a subgroup analysis of their ZETA-1 Phase 2 trial focusing on patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).
• The analysis examined a subset of patients with a Diabetic Retinopathy Severity Scale (DRSS) score of 47 or 53 in at least one eye and no center-involved diabetic macular edema (CI-DME) at baseline.
• The study compared the effects of APX3330, a drug being investigated for diabetic retinopathy, against a placebo.
• The primary endpoint was the percentage of subjects with a 2-step improvement in monocular ETDRS DRSS at Week 24.
• The analysis also looked at 3-step worsening or improvement on a binocular DRSS person-level scale, best-corrected visual acuity (BCVA), and the development of proliferative diabetic retinopathy (PDR).
• The NPDR subset included 59 patients, while the original ZETA-1 trial included 97 patients with both eyes evaluable for DRSS.
• The results showed that the NPDR subset amplified the treatment effect of APX3330, with fewer subjects worsening and more improving compared to the placebo group.

Sentiment

Score: 8

Explanation: The document presents positive results from a subgroup analysis, indicating a potential treatment benefit for APX3330. The results are promising and suggest a positive outlook for the drug's development.

Positives

• The NPDR subset analysis showed a clear treatment benefit for APX3330.
• The analysis demonstrated a reduction in the risk of worsening diabetic retinopathy with APX3330.
• The study showed a lower incidence of PDR development in the APX3330 group.
• APX3330 was well-tolerated with a similar safety profile to the placebo.
• The results support further investigation of APX3330 in high-risk NPDR patients.

Negatives

• The analysis is a post-hoc subgroup analysis, which may have limitations compared to a pre-planned study.
• The study only included a subset of the original ZETA-1 trial participants.
• Some patients in the study experienced adverse events, although they were generally mild and self-limited.

Risks

• The results are from a Phase 2 trial and need to be confirmed in larger Phase 3 trials.
• The post-hoc nature of the analysis may introduce bias.
• The study population was limited to a specific subgroup of NPDR patients.
• The long-term efficacy and safety of APX3330 are still unknown.

Future Outlook

The NPDR subset analysis informs a planned clinical trial investigating APX3330 in slowing PDR conversion in high-risk NPDR patients.

Management Comments

• Representatives of Ocuphire Pharma plan to share the presentation in upcoming meetings with investors and others.

Industry Context

This announcement is relevant to the broader pharmaceutical industry focused on developing treatments for diabetic retinopathy, a significant cause of vision loss. The results suggest a potential new treatment option for patients at high risk of progressing to PDR.

Comparison to Industry Standards

• The study uses the ETDRS DRSS and binocular DRSS, which are well-established scales for evaluating diabetic retinopathy, making the results comparable to other studies in the field.
• The results are promising compared to existing treatments, which often involve invasive procedures like laser photocoagulation or injections.
• Companies like Regeneron and Roche have established treatments for diabetic retinopathy, but there is still a need for oral therapies like APX3330.
• The results suggest that APX3330 could be a competitive option in the market if it continues to show positive results in future trials.

Stakeholder Impact

• The positive results could be beneficial for shareholders, as they suggest a potential new revenue stream for the company.
• Patients with diabetic retinopathy may benefit from a new treatment option.
• The results could also impact the company's employees, as they may be involved in further development and commercialization of APX3330.

Next Steps

• Ocuphire plans to conduct a clinical trial investigating APX3330 in slowing PDR conversion in high-risk NPDR patients.

Key Dates

Keywords

Diabetic Retinopathy, NPDR, APX3330, ZETA-1, Clinical Trial, PDR, Ocuphire Pharma, DRSS, Binocular DRSS, Treatment Benefit